编者按：2024年欧洲肿瘤内科学会（ESMO）年会将于9月13日~17日在西班牙巴塞罗那召开。会议旨在为来自世界各地的肿瘤领域专家学者提供一个学习平台，传递有望改变临床实践现状的科研数据，进一步丰富患者的治疗选择。

近日，ESMO官网重磅公布了部分口头摘要和壁报的标题，《肿瘤瞭望消化时讯》按专场对消化系统肿瘤领域的Proffered Paper和Mini Oral摘要内容进行了整理，以飨读者。

Proffered paper session 2: 新药研发与治疗创新专场

摘要号：609O英文标题：CLDN18.2 targeted antibody-drug conjugate (ADC), SHR-A1904, in patients (pts) with gastric/gastroesophageal junction cancer (GC/GEJC): a phase 1 study中文标题：靶向CLDN18.2的抗体药物偶联物（ADC）SHR-A1904治疗胃/胃食管结合部癌（GC/GEJC）：一项Ⅰ期研究讲者：徐瑞华 教授（中山大学肿瘤防治中心）

Proffered paper session 2: 上消化道肿瘤专场

摘要号：1400O英文标题：Final overall survival for the phase 3, KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+ advanced, unresectable or metastatic G/GEJ adenocarcinoma中文标题：帕博利珠单抗联合曲妥珠单抗和化疗治疗HER2+晚期、不可切除或转移性G/GEJ腺癌的Ⅲ期KEYNOTE-811研究的最终总生存期讲者：Yelena Y. Janjigian

摘要号：1401O英文标题：Trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2-positive (HER2+) esophageal, gastric or gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03 (DG-03)中文标题：德曲妥珠单抗（T-DXd）单药和联合治疗晚期或转移性HER2阳性（HER2+）食管、胃或胃食管结合部腺癌（GEJA）患者：DESTINY-Gastric03（DG-03）讲者：Yelena Y. Janjigian

Proffered paper session 1: 下消化道肿瘤专场

摘要号：502O英文标题：Pembrolizumab in combination with CAPOX and bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: preliminary results of FFCD 1703 POCHI trial中文标题：帕博利珠单抗联合CAPOX和贝伐珠单抗治疗微卫星稳定型、高免疫浸润转移性结直肠癌：FFCD 1703 POCHI研究的初步结果讲者：David Tougeron
摘要号：503O英文标题：Neoadjuvant nivolumab (nivo) plus relatlimab (rela) in MMR-deficient colon cancer: Results of the NICHE-3 study中文标题：纳武利尤单抗（nivo）联合relatlimab（rela）新辅助治疗dMMR型结肠癌：NICHE-3研究的结果讲者：Peter G. De Gooyer
摘要号：504O英文标题：IMHOTEP Phase II trial of neoadjuvant pembrolizumab in dMMR/MSI tumors: results of the colorectal cancer cohort中文标题：新辅助帕博利珠单抗治疗dMMR/MSI肿瘤的Ⅱ期IMHOTEP研究：结直肠癌队列的结果讲者：Christelle De la Fouchardiere

Proffered paper session 2: 下消化道肿瘤专场

摘要号：505O英文标题：Sotorasib (soto), panitumumab (pani) and FOLFIRI in the first-line (1L) setting for KRAS G12C–mutated metastatic colorectal cancer (mCRC): Safety and efficacy analysis from the phase 1b CodeBreaK 101 study中文标题：Sotorasib（soto）、帕尼单抗（pani）联合FOLFIRI一线（1L）治疗KRAS G12C突变的转移性结直肠癌（mCRC）：来自Ⅰb期CodeBreaK 101研究的安全性和有效性分析讲者：Salvatore Siena
摘要号：506O英文标题：Evaluation of risk of disease progression in first-line therapy of unresected metastatic colorectal cancer to guide intervals of radiological assessment- an analysis of eleven randomized trials by AIO and GONO中文标题：未切除转移性结直肠癌一线治疗中的疾病进展风险评价，用以指导放射学评估间隔——AIO和GONO对11项随机试验的分析讲者：Marco M. Germani (Pisa, Italy)

Mini oral session: 上消化道肿瘤专场

摘要号：1402MO英文标题：An international study evaluating pathological response to guide adjuvant FLOT chemotherapy in gastroesophageal cancer中文标题：一项通过评估病理缓解情况以指导胃食管癌症辅助FLOT化疗的国际研究讲者：Margaret M. Lee
摘要号：1504MO英文标题：Phase 2 Trial of Pembrolizumab and OLApaRib (POLAR) Maintenance for Select Patients (pts) with Metastatic Pancreatic Cancer (mPC) with (A) Homologous Recombination Deficiency (HRD), (B) non-core HRD (ncHRD) and (C) Exceptional Response to Platinum中文标题：帕博利珠单抗联合奥拉帕利（POLAR）维持治疗选定的（A）同源重组修复缺陷（HRD）、（B）非核心HRD（ncHRD）和（C）对铂类反应优异的转移性胰腺癌（mPC）患者的Ⅱ期研究讲者：Wungki Park

Mini oral session: 下消化道肿瘤专场

摘要号：507MO英文标题：Impact of lean body mass-based oxaliplatin dosage on neurotoxicity in adjuvant treatment of stage III colorectal cancer. Final results of the phase II randomized multicenter LEANOX trial中文标题：以去脂体重为基础的奥沙利铂剂量在Ⅲ期结直肠癌辅助治疗中对神经毒性的影响：Ⅱ期随机多中心LEANOX研究的最终结果讲者：Eric Assenat
摘要号：508MO英文标题：Organ preservation in early rectal adenocarcinoma: 5-year results of the randomized opera trial中文标题：早期直肠腺癌的器官保留：随机OPERA试验的5年结果讲者：Syrine Ben Dhia
摘要号：509MO英文标题：Total Neoadjuvant Treatment (TNT) with Non-Operative Management (NOM) for Proficient Mismatch Repair Locally Advanced Rectal Cancer (pMMR LARC): First Results of NO-CUT Trial中文标题：全程新辅助治疗（TNT）和非手术治疗（NOM）治疗错配修复正常的局部晚期直肠癌（pMMR LARC）患者：NO-CUT研究的首次结果讲者：Alessio Amatu
摘要号：510MO英文标题：Long-Term Survival and Organ Preservation with Pembrolizumab in Localized MSI-H/dMMR Solid Tumors中文标题：帕博利珠单抗治疗局限性MSI-H/dMMR实体瘤的长期生存和器官保留讲者：Kaysia Ludford
摘要号：511MO英文标题：Third line rechallenge with cetuximab (Cet) and irinotecan in circulating tumor DNA (ctDNA) selected metastatic colorectal cancer (mCRC) patients: the randomized phase II CITRIC trial中文标题：西妥昔单抗（Cet）联合伊立替康治疗循环肿瘤DNA（ctDNA）选定的转移性结直肠癌（mCRC）患者的三线再挑战：随机Ⅱ期CITRIC研究讲者：Cristina Santos Vivas
摘要号：512MO英文标题：Adjuvant Aspirin Treatment in PIK3CA Mutated Colon Cancer Patients – The Phase III, Prospective-Randomized Placebo-Controlled Multicenter SAKK 41/13 Trial中文标题：阿司匹林辅助治疗PIK3CA突变结肠癌患者：Ⅲ期、前瞻性、随机、安慰剂对照、多中心SAKK 41/13研究讲者：Ulrich Güller
摘要号：513MO英文标题：Amivantamab plus FOLFOX or FOLFIRI in metastatic colorectal cancer: Results from OrigAMI-1, an open-label, phase 1b/2 study中文标题：Amivantamab联合FOLFOX或FOLFIRI治疗转移性结直肠癌患者：来自开放标签、Ⅰb/Ⅱ期OrigAMI-1研究的结果讲者：Filippo Pietrantonio

Proffered paper session: 神经内分泌肿瘤专场

摘要号：1141O英文标题：Cabozantinib Versus Placebo for Advanced Neuroendocrine Tumors (NET) after Progression on Prior Therapy (CABINET Trial/Alliance A021602): Updated Results Including Progression Free-Survival (PFS) by Blinded Independent Central Review (BICR) and Subgroup Analyses.中文标题：Cabozantinib对比安慰剂用于既往治疗后进展的晚期神经内分泌肿瘤（CABINET Trial/Alliance A021602）：包括盲法独立中心评审的无进展生存期（PFS）及亚组分析在内的最新结果讲者：Jennifer Chan
摘要号：1142O英文标题：Multivariable Analysis of Streptozotocin plus 5-Fluorouracil and Everolimus Sequences in Advanced Pancreatic Neuroendocrine Tumor patients: The SEQTOR Trial (GETNE-1206).中文标题：链脲霉素+5-FU和依维莫司不同治疗序列应用于晚期胰腺神经内分泌肿瘤的多变量分析：SEQTOR试验（GETNE-1206）讲者：Jaume Capdevila Castillon
摘要号：1143O英文标题：Refining molecular classification of neuroendocrine tumors from diverse origins using multi-omic integration models. Unveiling novel neuroendocrine subtypes and their clinical implications.中文标题：利用多组学整合模型改进来自不同来源的神经内分泌肿瘤的分子分类，揭示新的神经内分泌亚型及其临床意义讲者：Carlos Carretero-Puche
摘要号：1144O英文标题：Osteopontin (OPN) predicts the efficacy of anti-angiogenic therapy with multikinase inhibitors (MKIs) in advanced neuroendocrine tumors (NETs): underlying molecular mechanisms.中文标题：骨桥蛋白可预测抗血管生成疗法联合多激酶抑制剂（MKIs）在晚期神经内分泌肿瘤（NETs）中的疗效：潜在的分子机制讲者：Alberto Lens-Pardo

Mini oral session: 神经内分泌肿瘤专场

摘要号：1925MO英文标题：Regomune study : A phase II study of regorafenib + avelumab in solid tumors.中文标题：Regomune研究：一项关于瑞戈非尼+阿维鲁单抗在实体瘤中的II期研究讲者：Yann Godbert
摘要号：1145MO英文标题：CVM-005: Phase IIa study of CVM-1118, a novel oral anti-vasculogenic mimicry (VM) agent, in advanced neuroendocrine tumors (NET) after progression on prior therapy

中文标题：CVM-005：新型口服抗血管生成拟态（VM）剂CVM-1118用于既往治疗后进展的晚期神经内分泌肿瘤（NET）的Ⅱa期研究

讲者：Chia Jui Yen
摘要号：1146MO英文标题：Interim analysis of CABONEN – a multicenter phase II trial investigating Cabozantinib in patients with advanced, low proliferative NEN G3中文标题：探索Cabozantinib在晚期低增殖活性神经内分泌肿瘤G3患者中疗效的多中心Ⅱ期试验CABONEN的中期分析讲者：Alexander Otto Koenig
摘要号：1147MO英文标题：Ramucirumab in combination with dacarbazine in patients with progressive well-differentiated metastatic pancreatic neuroendocrine tumors (RamuNET): An AIO phase II multicenter single-arm study中文标题：雷莫西尤单抗联合达卡巴嗪治疗进展性、高分化转移性胰腺神经内分泌肿瘤RamuNET）：一项AIO II期多中心单臂研究讲者：Sebastian Krug
摘要号：1148MO英文标题：A Multivariate Efficacy Analysis of [177Lu]Lu-DOTA-TATE in the NETTER 2 Study中文标题：NETTER 2研究中[177Lu]Lu-DOTA-TATE的多变量疗效分析讲者：Marianne E. Pavel
摘要号：1149MO英文标题：Carcinoid Heart Disease in Patients with Advanced Small-intestinal Neuroendocrine Tumours and Carcinoid Syndrome: A Retrospective experience of two Centers of Excellence中文标题：晚期小肠神经内分泌肿瘤和类癌综合征患者类癌心脏病的回顾性研究：两个卓越中心的经验讲者：Laura Algeri

0